Prime Medicine, Inc. (PRME) stock forecast and price target
Price $4.27 · data as of November 13, 2026
12-month price target
Average target$7.03
Upside / downside+64.5%
Analysts10
ConsensusBuy
Low $4.25Average $7.03High $9.00
Gold marker: average target · white marker: today’s price ($4.27)
Analyst ratings
Strong buy 1Buy 9Hold 3Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-0.91 | +32.5% | $8M |
| Next fiscal year ends December 31, 2027 | $-0.83 | +9.2% | $11M |
| Next quarter ends December 31, 2026 | $-0.21 | +11.1% | $6M |
| Quarter after ends March 31, 2027 | $-0.23 | +18.5% | $1M |
Consensus of the analysts covering Prime Medicine, updated daily. In the last 30 days 7 estimates were raised and 3 lowered.
Frequently asked questions
What is the Prime Medicine stock price target?
The average 12-month target from 10 analysts is $7.03, 64.5% above the current price of $4.27 Targets range from $4.25 to $9.00.
Is Prime Medicine a buy according to analysts?
The consensus rating is “Buy” (1 strong buy, 9 buy, 3 hold). Ratings are opinions, not guarantees; this is not investment advice.
How much is Prime Medicine expected to earn?
Analysts expect EPS of $-0.91 for the fiscal year ending December 31, 2026 and $-0.83 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.